An efficient chemical approach to bispecific antibodies and antibodies of high valency

Article abstract of DOI:10.1016/j.bmcl.2009.05.047

Irreversible chemical programming of monoclonal aldolase antibody (mAb) 38C2 has been accomplished with β-lactam equipped mono- and bifunctional targeting modules, including a cyclic-RGD peptide linked to either the peptide (d-Lys⁶)-LHRH or ano

Full text of DOI:10.1016/j.bmcl.2009.05.047

Bioorganic & Medicinal Chemistry Letters 19 (2009) 3716–3720
Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier.com/locate/bmcl
An efficient chemical approach to bispecific antibodies and antibodies
of high valency
Julia I. Gavrilyuk, Ulrich Wuellner, Syed Salahuddin, Rajib K. Goswami, Subhash C. Sinha,
*
Carlos F. Barbas III
The Skaggs Institute for Chemical Biology and the Departments of Chemistry and Molecular Biology,
The Scripps Research Institute, 10550 North Torrey Pines Rd. La Jolla, CA 92037, USA
a r t i c l e i n f o
a b s t r a c t
Article history:
Irreversible chemical programming of monoclonal aldolase antibody (mAb) 38C2 has been accomplished
Received 18 March 2009
Revised 12 May 2009
Accepted 13 May 2009
Available online 18 May 2009
with b-lactam equipped mono- and bifunctional targeting modules, including a cyclic-RGD peptide
linked to either the peptide (
inhibitor SCS-873 conjugated to (
taining either cyclic RGD or (
-Lys6)-LHRH peptides. Binding of the chemically programmed antibodies to
integrin receptors (v)b(3) and (v)b(5) and to the luteinizing hormone releasing hormone receptor were
D
-Lys6)-LHRH or another cyclic RGD unit and a small-molecule integrin
D
-Lys6)LHRH. We also prepared monofunctional targeting modules con-
D
a
a
Keywords:
evaluated. The bifunctional and bivalent c-RGD/LHRH and SCS-783/LHRH, the monofunctional and tetra-
valent c-RGD/c-RGD, and the monofunctional bivalent c-RGD chemically programmed antibodies bound
specifically to the isolated integrin receptor proteins as well as to integrins expressed on human mela-
noma M-21 cells. c-RGD/LHRH, SCS-783/LHRH, and LHRH chemically programmed antibodies bound spe-
cifically to the LHRH receptors expressed on human ovarian cancer cells. This approach provides an
efficient, versatile, and economically viable route to high-valency therapeutic antibodies that target
defined combinations of specific receptors. Additionally, this approach should be applicable to chemically
programmed vaccines.
Chemically programmed antibodies
Monoclonal antibody
Aldolase antibody
Valency
Ó 2009 Elsevier Ltd. All rights reserved.
Chemically programmed antibodies (cpAbs) are a new class of
therapeutic molecules that result from the marriage of medicinal
chemistry and protein engineering. In this approach an antibody
is programmed through chemistry to bind a target of biological
interest; the programmed antibody maintains advantages charac-
teristic of both antibodies and the targeting agent. Selective and
irreversible chemical programming of the aldolase antibody 38C2
can be accomplished via amide bond formation between the low
pKa catalytic site lysine H931,2 and b-lactam equipped targeting
modules.3,4 Early studies focused on the programming of mAb
antibodies with multiple specificities and to antibodies of high
valency.
In our model study, we combined integrin avb3 and avb5 tar-
geting with luteinizing hormone releasing hormone (LHRH) recep-
tor targeting to create a molecule that has the potential for a
synergistic double strike against tumor and supporting vascula-
ture. Integrins avb3 and avb5 are well-established targets for can-
cer therapy, as these receptors are critical for tumor angiogenesis
and metastasis.11–13 However, cancer therapy would likely be more
efficacious if another tumor-associated antigen could also be tar-
geted. In general, co-targeting should allow for more precise tar-
geting of varied cell-types in multiple diseases. The LHRH
receptor is a promising target since it is not expressed in most nor-
mal tissues whereas binding sites for LHRH are found cells isolated
from 52% of human breast cancers, about 80% of human ovarian
and endometrial cancers, and 86% of human prostate carcinoma
specimens.14–17 Targeting of cancer cells through two different
receptor pathways should make the development of resistance less
likely since down regulation of more than one receptor would be
required. Further, we expect that the antibody therapeutic should
be more potent as the antibody load onto the targeted cells will
be increased thereby increasing the effective coupling of bound
antibody to the immune system via complement- and cell-depen-
dent mechanisms.
38C2 with integrin avb3 and a
vb5 targeting units.3,5–9
It has long been recognized that antibodies with the ability to
bind to more than one target protein might have a therapeutic
advantage in treating disease. Despite numerous attempts over
the past two decades to develop viable approaches to synthesis
of bi- and multi-specific antibodies, no such antibodies are ap-
proved drugs. Protein engineering approaches for the creation of
bispecific antibodies have been challenging due to issues of protein
stability and difficulties in obtaining high-level expression. Indeed,
only recently have promising breakthroughs been reported.10 Here
we demonstrate a method that provides an efficient route to
* Corresponding author. Tel.: +1 858 784 9098; fax: +1 858 784 2583.
E-mail address: carlos@scripps.edu (C.F. Barbas).
0960-894X/$ - see front matter Ó 2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmcl.2009.05.047

J. I. Gavrilyuk et al. / Bioorg. Med. Chem. Lett. 19 (2009) 3716–3720
3717
The linkers used to connect integrin
a
vb3 and
avb5 targeting
Asp-D-Phe-Lys)), commercially available from Peptides Interna-
and LHRH receptor targeting units are unlikely, due to steric rea-
sons, to enable each arm to simultaneously bind more than one
receptor. The antibody complexes are expected to bind LHRH
receptor and integrin, two LHRH receptors, or two integrins
(Fig. 1). In order to dissect the relative contribution of each compo-
nent of our multifunctional chemically programmed (cp) Ab 38C2,
each constituent was independently synthesized as a b-lactam
containing targeting unit and directly coupled to antibody 38C2.
Monofunctional integrin targeting unit 4 was synthesized by
tional, Inc., to give corresponding azide 2 (Scheme 1). Copper-cata-
lyzed azide–alkyne cycloaddition20,21 of 2 with heterobifunctional
b-lactam linker 3 provided the desired targeting module 4 in excel-
lent yield. Similarly, the
e-amino group of D D
-Lys6 in ( -Lys6)
LHRH14,17 (commercially available from Bachem) was reacted with
1 followed by click reaction with 3 to provide the monofunctional
LHRH-targeting module 6.
We evaluated two different integrin targeting modules, the cyc-
lic-RGD peptide and the peptidomimetic SCS-873. These molecules
were combined with the LHRH targeting unit in the bifunctional
b-lactam equipped molecule. Targeting module 9 containing two
conjugation of NHS-PEG-azide linker 1 with the
e-amino group of
the lysine moiety in the cyclic-RGD peptide18,19 (cyclo(Arg-Gly-
Figure 1. Schematic representation of possible binding modes for a bispecific cpAb and a tetravalent cpAb.
Scheme 1. Synthesis of the targeting modules 4 and 6.

3718
J. I. Gavrilyuk et al. / Bioorg. Med. Chem. Lett. 19 (2009) 3716–3720
Scheme 2. Synthesis of the bi/trifunctional targeting modules 9 and 10.
Scheme 3. Synthesis of building block 13.
Scheme 4. Synthesis of the targeting module 18.
cyclic-RGD peptide units was also prepared. Bi- and trifunctional
targeting modules 9, 10, and 18 were prepared on a milligram
scale. Cyanuric chloride 7 was used as a platform for sequential
functionalization following established procedures.22–24 Cyanuric
chloride was sequentially reacted with propargyl amine in the
presence of diisopropyl ethyl amine, followed by click reaction
with corresponding azido functionalized peptide as shown in
Scheme 2. b-lactam linker 3 was introduced using a click reaction
followed by removal of copper with copper scavenging resin and
cold ether trituration of the products 9 or 10.
isolated yield. Subsequent treatment with trifluoroacetic acid in
dichloromethane deprotected the amine linker arm to furnish
intermediate 17 in 91% isolated yield. Compound 16 was treated
with 1 N NaOH to remove the methyl ester from the SCS-873 mod-
ule followed by coupling of the free amine to activated NHS-ester
of LHRH module 13. Click coupling of the alkynyl subunit contain-
In order to prepare bi/trifunctional targeting module 18, the
NHS-activated ester 13 of (D
-Lys6)LHRH was prepared (Scheme
3). Ethyl 4-hydroxybenzoate 11 was reacted with propargyl bro-
mide in the presence of potassium carbonate in DMF to afford
the alkynyl ester 12 in 95% isolated yield. The ester was hydrolyzed
using lithium hydroxide followed by coupling with N-hydroxy-
succinimide in the presence of DCC and catalytic DMAP. Click reac-
tion of corresponding NHS-alkyne with azido-functionalized LHRH
module 5 provided desired activated ester 13.
Cyanuric chloride 7 was monosubstituted with tert-butyl 1-hy-
droxy-3,6,9,12-tetraoxapentadecan-15-ylcarbamate in the pres-
ence of Hunig’s base (Scheme 4), followed by subsequent
substitution with ethyl 4-aminobutanoate to provide product 13
in 58% isolated yield. Substitution of the last chlorine with propar-
gyl amine in the presence of Hunig’s base under reflux in THF was
followed by ester hydrolysis with lithium hydroxide to provide
intermediate 14. Free acid was coupled to the SCS-873 methyl es-
ter 168 in the presence of BOP chloride and triethylamine in 20%
Figure 2. Results of the integrin binding ELISA assay. Unprogrammed mAb 38C2
was used as a negative control,
avb3 specific antibody LM609 and avb5 specific
antibody P1F6 (Chemicon) were used as positive controls.

J. I. Gavrilyuk et al. / Bioorg. Med. Chem. Lett. 19 (2009) 3716–3720
3719
by HPLC and MALDI-TOF confirming desired molecular weights
and good to excellent purities.
Mono- and polyfunctional targeting modules 4, 6, 9, 10, and 18
were used for the chemical programming of mAb 38C2 as previ-
ously described.2 mAb 38C2 was incubated with 2 equiv of the tar-
geting unit at room temperature for 2–3 h. Complete loss of
catalytic activity in the methodol-based catalytic assay9 indicated
Lys H93 labeling. Each of the mono- and bi/trifunctional chemically
programmed antibodies was characterized by SEC/MS to confirm
incorporation of two targeting units per antibody (see Supplemen-
tary data).
The mono- and bi-functional antibodies were tested for integrin
binding by ELISA. Chemically programmed antibody constructs
38C2/4, 38C2/9, 38C2/10, and 38C2/18 bound to integrin receptors
a
vb3 and avb5 but not to IIb3a (Fig. 2), whereas the (D
-Lys6)LHRH-
programmed 38C2 did not bind to the integrin receptors. Tetrava-
lent cRGD/cRGD cpAb demonstrated enhanced binding to integrin
as compared with bivalent cRGD cpAb (data not shown). Binding to
M-21 cells, which express integrin receptor but not LHRH receptor,
was evaluated by flow cytometry analysis.7 Only chemically pro-
grammed antibodies containing SCS-873 or cyclic-RGD peptide
bound to the M-21 cell surface (Fig. 3). All of the chemically pro-
grammed antibodies bound to ES-2 cells, which express both types
of receptors (Fig. 3).
In conclusion, we have developed a versatile linker strategy for
mono- and bi-functional chemical programming of the aldolase
antibody 38C2. This chemistry should also be applicable to cyto-
toxin delivery. By selection of the targeting unit, this approach al-
lows for the creation of antibodies that simultaneously target
several different receptors, such as integrin receptors
avb3 and
avb5 and LHRH receptor demonstrated here. This method pro-
vides a convenient approach to synthesis of multifunctional anti-
bodies and antibodies of high valency and should be directly
applicable to chemically programmed vaccines.25 We anticipate
that the ability to target defined collections of antigens with
our approach will allow for more precise targeting of varied
cell-types in multiple diseases wherein the net avidity obtained
by engaging the various targeting arms drives selectivity to cells
expressing the targeted antigen constellation. This level of dis-
crimination is not possible through the simple administration of
mixtures of mono-targeting antibodies. Finally, as we develop
new types of drugs, economic realities must also be considered.
Monoclonal antibody therapy can cost over $100,000.00 per year.
Treatment with defined combinations of monoclonal antibodies
are expected to show therapeutic advantages, however, the cost
of such therapies will preclude their consideration as viable treat-
ments for most individuals. We anticipate that our approach will
lead to superior drugs with substantially reduced costs as com-
pared to combinations of monoclonal antibodies, thereby making
them an economically viable drug class. Further biological evalu-
ation of the mono- and bi/tri-specific chemically programmed
antibodies and vaccines is underway and will be reported in the
due course.
Figure 3. Results of the flow cytometry analysis. Controls for M-21 cell line: cells
only (red line); anti-LHRH receptor antibody (Abcam) (green); Cy-5 conjugated
secondary anti-mouse antibody (purple); Cy-5 conjugated secondary anti-rabbit
antibody (light blue); P1F6 (brown); LM609 (blue). Controls for ES2 cell line: cells
only (red line); Cy-5 conjugated secondary anti-mouse antibody (brown); Cy-5
conjugated secondary anti-rabbit antibody (blue); anti-LHRH receptor antibody
(9652615, Abcam) (green); P1F6 (purple); LM609 (light blue). Antibody binding
experiments: 38C2 binding (red line), cp Ab bindings (green line).
Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bmcl.2009.05.047.
References and notes
ing SCS-873 and LHRH modules to the b-lactam azide linker 3 com-
pleted the synthesis of bi/trifunctional targeting module 18. Cop-
per has been removed using copper scavenging resin and product
18 has been isolated by cold ether triturating in 71% overall yield
for last three steps. All the targeting modules were characterized
1. Wagner, J.; Lerner, R. A.; Barbas, C. F., III Science 1995, 270, 1797.
2. Barbas, C. F., III; Heine, A.; Zhong, G. F.; Hoffmann, T.; Gramatikova, S.;
Bjornestedt, R.; List, B.; Anderson, J.; Stura, E. A.; Wilson, I. A.; Lerner, R. A.
Science 1997, 278, 2085.
3. Gavrilyuk, J. I. W. U.; Barbas, C. F., III Bioorg. Med. Chem. Lett. 2009, 19, 1421.
4. Tanaka, F.; Lerner, R. A.; Barbas, C. F., III Chem. Commun. 1999, 1383.

3720
J. I. Gavrilyuk et al. / Bioorg. Med. Chem. Lett. 19 (2009) 3716–3720
5. Guo, F.; Das, S.; Mueller, B. M.; Barbas, C. F., III; Lerner, R. A.; Sinha, S. C. Proc.
Natl. Acad. Sci. U.S.A. 2006, 103, 11009.
6. Li, L. S.; Rader, C.; Matsushita, M.; Das, S.; Barbas, C. F., III; Lerner, R. A.; Sinha, S.
C. J. Med. Chem. 2004, 47, 5630.
15. Nagy, A.; Schally, A. V. Biol. Reprod. 2005, 73, 851.
16. Engel, J. B.; Schally, A. V. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3, 157.
17. Keller, G.; Schally, A. V.; Gaiser, T.; Nagy, A.; Baker, B.; Westphal, G.; Halmos,
G.; Engel, J. B. Cancer Res. 2005, 65, 5857.
7. Popkov, M.; Rader, C.; Gonzalez, B.; Sinha, S. C.; Barbas, C. F., III Int. J. Cancer
2006, 119, 1194.
8. Rader, C.; Sinha, S. C.; Popkov, M.; Lerner, R. A.; Barbas, C. F., III Proc. Natl. Acad.
Sci. U.S.A. 2003, 100, 5396.
18. Garanger, E.; Boturyn, D.; Dumy, P. Anticancer. Agents Med. Chem. 2007, 7, 552.
19. Meyer, A.; Auernheimer, J.; Modlinger, A.; Kessler, H. Curr. Pharm. Des. 2006, 12,
2723.
20. Destito, G.; Yeh, R.; Rae, C. S.; Finn, M. G.; Manchester, M. Chem. Biol. 2007, 14,
9. Sinha, S. C.; Das, S.; Li, L. S.; Lerner, R. A.; Barbas, C. F., III Nat. Prot. 2007, 2, 449.
10. Wu, C.; Ying, H.; Grinnell, C.; Bryant, S.; Miller, R.; Clabbers, A.; Bose, S.;
McCarthy, D.; Zhu, R. R.; Santora, L.; Davis-Taber, R.; Kunes, Y.; Fung, E.;
Schwartz, A.; Sakorafas, P.; Gu, J.; Tarcsa, E.; Murtaza, A.; Ghayur, T. Nat.
Biotechnol. 2007, 25, 1290.
11. Friedlander, M.; Brooks, P. C.; Shaffer, R. W.; Kincaid, C. M.; Varner, J. A.;
Cheresh, D. A. Science 1995, 270, 1500.
12. Wong, N. C.; Mueller, B. M.; Barbas, C. F., III; Ruminski, P.; Quaranta, V.; Lin, E.
C.; Smith, J. W. Clin. Exp. Metast. 1998, 16, 50.
1152.
21. Devaraj, N. K.; Collman, J. P. Qsar. Comb. Sci. 2007, 26, 1253.
22. Huang, W.; Zheng, W.; Urban, D. J.; Inglese, J.; Sidransky, E.; Austin, C. P.;
Thomas, C. J. Bioorg. Med. Chem. Lett. 2007, 17, 5783.
23. Jarman, M.; Coley, H. M.; Judson, I. R.; Thornton, T. J.; Wilman, D. E.; Abel, G.;
Rutty, C. J. J. Med. Chem. 1993, 36, 4195.
24. Liu, S.; Zavalij, P. Y.; Lam, Y. F.; Isaacs, L. J. Am. Chem. Soc. 2007, 129,
11232.
25. Popkov, M.; Gonzalez, B.; Sinha, S.; Barbas, C. F., III Proc. Natl. Acad. Sci. U.S.A.
2009, 106, 4378.
13. Eliceiri, B. P.; Cheresh, D. A. Mol. Med. 1998, 4, 741.
14. Keller, G.; Schally, A. V.; Gaiser, T.; Nagy, A.; Baker, B.; Halmos, G.; Engel, J. B.
Clin. Cancer Res. 2005, 11, 5549.